复发性基因突变对慢性淋巴细胞白血病预后影响因IGHV基因体细胞超突变状态而异:ERIC在HARMONY中的研究
该研究基于4580例慢性淋巴细胞白血病(CLL)患者治疗前样本,以至首次治疗时间(TTFT)为主要终点,分析9个复发性突变基因与IGHV基因体细胞超突变(SHM)状态的关系。除MYD88外,所有基因突变均与显著缩短的TTFT相关;在IGHV突变型(M-CLL)与未突变型(U-CLL)中,独立预测短TTFT的基因谱不同。
要点
- 1588例(34.7%)患者检出突变,频率2.3%-9.8%,NOTCH1突变最常见。
- 除MYD88外,所有基因突变在单变量和多变量分析中均与显著缩短的TTFT相关。
- SF3B1和XPO1突变在U-CLL和M-CLL中均为独立预后变量,TP53、BIRC3、EGR2仅U-CLL显著,NOTCH1、NFKBIE仅M-CLL显著。
核心结论
- 复发性基因突变对CLL预后的影响因IGHV基因SHM状态而异,尤其M-CLL患者需分区策略识别高危。
研究设计与样本
- ERIC在HARMONY开展的研究,纳入4580例CLL患者治疗前样本,以TTFT为主要终点,分析9个复发性突变基因与IGHV基因SHM状态的关系。
主要发现
- 1588例(34.7%)患者检出突变,频率范围2.3%-9.8%,NOTCH1突变最常见。
- 单变量和多变量分析中,除MYD88外所有基因突变均与显著缩短的TTFT相关。
- Binet A期患者多变量分析(按IGHV突变型M-CLL和未突变型U-CLL分别进行)显示,SF3B1和XPO1突变在U-CLL和M-CLL中均为独立预后变量,TP53、BIRC3和EGR2异常仅在U-CLL中为显著预测因素,NOTCH1和NFKBIE仅在M-CLL中为显著预测因素。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on the immunoglobulin heavy variable (IGHV) gene somatic hypermutation (SHM) status. In this study, we assessed the impact of nine recurrently mutated genes (BIRC3, EGR2, MYD88, NFKBIE, NOTCH1, POT1, SF3B1, TP53, and XPO1) in pre-treatment samples from 4580 patients with CLL, using time-to-first-treatment (TTFT) as the primary end-point in relation to IGHV gene SHM status. Mutations were detected in 1588 (34.7%) patients at frequencies ranging from 2.3-9.8% with mutations in NOTCH1 being the most frequent. In both univariate and multivariate analyses, mutations in all genes except MYD88 were associated with a significantly shorter TTFT. In multivariate analysis of Binet stage A patients, performed separately for IGHV-mutated (M-CLL) and unmutated CLL (U-CLL), a different spectrum of gene alterations independently predicted short TTFT within the two subgroups. While SF3B1 and XPO1 mutations were independent prognostic variables in both U-CLL and M-CLL, TP53, BIRC3 and EGR2 aberrations were significant predictors only in U-CLL, and NOTCH1 and NFKBIE only in M-CLL. Our findings underscore the need for a compartmentalized approach to identify high-risk patients, particularly among M-CLL patients, with potential implications for stratified management.
引用
- Mansouri L, Thorvaldsdottir B, Sutton LA, et al. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY. Leukemia. 2022. PMID: 36566271. doi:10.1038/s41375-022-01802-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。